These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18044260)

  • 1. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
    Abe M; Kikuchi F; Kaizu K; Matsumoto K
    Clin Nephrol; 2007 Nov; 68(5):287-94. PubMed ID: 18044260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis.
    Abe M; Kikuchi F; Okada K; Kaizu K; Matsumoto K
    Diabetes Res Clin Pract; 2008 Jun; 80(3):432-8. PubMed ID: 18346811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis.
    Abe M; Okada K; Kikuchi F; Matsumoto K
    Clin Nephrol; 2008 Sep; 70(3):220-8. PubMed ID: 18793563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis.
    Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
    Expert Opin Pharmacother; 2010 Feb; 11(2):169-76. PubMed ID: 20025554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.
    Abe M; Okada K; Maruyama T; Maruyama N; Soma M; Matsumoto K
    Expert Opin Pharmacother; 2010 Jul; 11(10):1611-20. PubMed ID: 20540652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
    Ishida H; Kato S; Nishimura M; Mizuno N; Fujimoto S; Mukai E; Kajikawa M; Yamada Y; Odaka H; Ikeda H; Seino Y
    Horm Metab Res; 1998 Nov; 30(11):673-8. PubMed ID: 9918384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
    Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
    Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
    Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
    Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
    Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
    Charpentier G; Halimi S;
    Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus.
    Rosenstock J; Truitt KE; Baz-Hecht M; Ford DM; Tao B; Chou HS
    Horm Metab Res; 2014 Dec; 46(13):943-9. PubMed ID: 25054436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
    Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
    Curr Med Res Opin; 2011 Nov; 27 Suppl 3():21-9. PubMed ID: 22106975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
    Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Zirie M; Jayyousi A
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2162-2170. PubMed ID: 28324038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
    Ono Y; Kameda H; Cho KY
    Expert Opin Pharmacother; 2013 Mar; 14(4):361-70. PubMed ID: 23414242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.
    Kutoh E
    Endocr Res; 2010; 35(3):118-27. PubMed ID: 20712426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.